Charles Schwab Investment Management Inc. Boosts Position in Omeros Co. (NASDAQ:OMER)

Charles Schwab Investment Management Inc. grew its holdings in shares of Omeros Co. (NASDAQ:OMER) by 4.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 485,035 shares of the biopharmaceutical company’s stock after buying an additional 18,454 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.84% of Omeros worth $1,926,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its position in Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after purchasing an additional 31,081 shares during the period. AQR Capital Management LLC purchased a new stake in shares of Omeros in the second quarter worth about $105,000. SG Americas Securities LLC purchased a new stake in shares of Omeros in the third quarter worth about $80,000. SPC Financial Inc. acquired a new stake in shares of Omeros in the third quarter valued at about $77,000. Finally, Cypress Capital Group raised its holdings in shares of Omeros by 40.0% during the 2nd quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 10,000 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Wall Street Analysts Forecast Growth

OMER has been the subject of a number of analyst reports. Rodman & Renshaw started coverage on Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target for the company. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Thursday, November 14th. Finally, StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Omeros presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Omeros Trading Down 0.5 %

Shares of NASDAQ:OMER opened at $7.59 on Tuesday. The firm has a market cap of $439.84 million, a PE ratio of -3.29 and a beta of 1.97. The company has a fifty day simple moving average of $6.68 and a 200 day simple moving average of $5.05. Omeros Co. has a 12-month low of $2.61 and a 12-month high of $12.65.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.